As of February 10, 2026

Please refer to local prescribing information for more information, including full safety information, on Incyte’s marketed medicines, or on medicines marketed by Incyte’s collaboration partners.

1. Marketed by Incyte in the U.S.; ruxolitinib licensed to Novartis outside the U.S. 2. Approved in the U.S. 3. Development in collaboration with Merus  4. In collaboration with Syndax 5. Approved in Canada 6. Approved in Europe 7. Approved in Japan
8. European rights to ponatinib licensed from Takeda 9. Licensed from MacroGenics 10. Approved in multiple territories, including the U.S., Canada, Europe, and Japan 11. Worldwide rights to baricitinib licensed to Lilly 12. Approved in multiple territories globally
13. Worldwide rights to capmatinib licensed to Novartis 14. IPF study currently led and funded by Syndax

1L, first-line; 3L+, third-line or later; AD, atopic dermatitis; ALL, acute lymphoblastic leukemia; CALR, calreticulin; DLBCL, diffuse large B-cell lymphoma; ET, essential thrombocythemia; FGFR, fibroblast growth factor receptor; GVHD, graft-versus-host disease; IPF, idiopathic pulmonary fibrosis; MLNs, myeloid/lymphoid neoplasms; MPNs, myeloproliferative neoplasms; mut, mutant; Ph+, Philadelphia chromosome-positive; PROC, platinum-resistant ovarian cancer; QD, once daily; r/r, relapsed or refractory; wAIHA, warm autoimmune hemolytic anemia; XR, extended release.